Glenmark Sued Over Carvedilol Nitrosamine Contamination — 17 Months After the First Recall

A proposed class action captioned Carroll v. Glenmark Pharmaceuticals Inc. USA, No. 2:26-cv-00327, is pending in the U.S. District Court for the Eastern District of Washington. Named plaintiff Sharon Carroll alleges that Glenmark's generic Carvedilol — the generic equivalent of the branded heart medication Coreg — contained nitrosamine impurities and was manufactured outside current federal quality standards.

The complaint seeks class certification, compensatory and punitive damages, injunctive relief and a jury trial. Counsel of record includes Kim D. Stephens, Cecily C. Jordan, Ruben Honik and David J. Stanoch.

The lawsuit follows two recall waves. In March 2025, Glenmark recalled more than 732,000 bottles of Carvedilol after an FDA inspection found manufacturing deviations and nitrosamine contamination. Further recalls followed in August 2025 over the same issue.

Nitrosamines are a family of compounds that regulators treat as probable human carcinogens above certain daily limits. They have driven recalls across several drug classes in recent years, including blood-pressure and heartburn medications.

This is framed as an economic-loss case, not a personal-injury case. Carroll's theory is that she would not have bought the medication at all, or would have paid less for it, had the contamination been disclosed. That distinction matters: economic-loss classes turn on what consumers paid, not on whether any individual became ill.

No court has ruled on the merits. A filed complaint contains allegations that Glenmark has not yet answered, and class certification has not been decided.

The publicly reported coverage does not identify the specific lot numbers the complaint targets, and no settlement of any kind exists. Anyone trying to work out whether a particular bottle was affected should check the FDA's recall listings for the lot code printed on the label rather than relying on news coverage.